ICHNOS SCIENCES PRESENTS PRECLINICAL DATA ON NOVEL ISB 1442 IN RELAPSED/REFRACTORY
ISB 1442 is a First-In-Class 2+1 Biparatopic Bispecific BEAT® 2.0 Antibody Targeting CD38 and CD47Data from Preclinical Models Suggest Higher Potency and Tumor Growth Inhibition for ISB 1442 Relative to DaratumumabEnrollment in the…